A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

What Was Tested

This registered phase 3 trial tested Eloralintide.

Participation in the study will last about 80 weeks.

It had five arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and Placebo (placebo comparator).

Participants will receive eloralintide subcutaneously (SC).

Participants will receive eloralintide SC.

Participants will receive eloralintide SC.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 900 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Are on stable incretin therapy at screening. With persistent obesity or overweight defined as:. ≥30 kg/m2 OR. ≥27 kg/m2 with at least one existing obesity related complication at screening:. Obstructive sleep apnea.

The full record lists 10 inclusion and 14 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening); have type 1 diabetes; have taken any of the following antihyperglycemic medications within 90 days before screening:.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Eloralintide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Eloralintide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2026-02-10 with completion listed for 2028-06.

It ran at 185 sites in United States (59), China (22), Israel (17), Japan (11), Australia (10) and India (10).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percent Change from Baseline in Body Weight (time frame: Baseline, Week 64).

It also tracked 15 secondary outcomes, for example Change from Baseline in Waist Circumference, Percent Change in Baseline in Triglycerides, Change from Baseline in Systolic Blood Pressure, Change from Baseline in Body Mass Index (BMI), Change from Baseline in Fasting Glucose in Participants with Type 2 Diabetes at Baseline and Change from Baseline in Short Form-36 (SF-36 v2) Score.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Eloralintide in 900 people.

With 900 participants it is a large trial for this field.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Eloralintide compound page, all human trials.